Deloitte China Life Sciences & Health Care (LSHC) team conducted our 4th annual “State of industry” survey for the LSHC market in China during 10th January to 23rd January 2023, to better understand pharmaceutical & healthcare players' situation in China with their 2022 final outcome and outlook for 2023.
We would like to thank all participants for providing insights covering a number of areas ranging from business performance, key elements impacting their business, their 2023 outlook as well as what changes will be impacting their business models, the usage of technologies and digitalization of their operations as a whole to cope with 'somewhat volatile internal and external environment'.
We have selected some few extracts from our report here below. We hope you'll be interested to know more, and you may download the full report. Of course, our team is available to individual and specific presentations where we can further elaborate on some of the details.
Insights
Insights
Insights
Insights
Insights
Note: [1] Large cos: enterprise with revenue above RMB 1 billion; [2] SOE: State-owned Enterprise; [3] POE: Private-owned Enterprise; [4] WOFE: Wholly Foreign-owned Enterprise; [5] Life Science: Pharma & Medical Devices
In Summary: China insight and outlook 2023: extracts from full survey report